Endo Paget Bisphosphonate Paraplegia Spine

---
name: endo-paget-bisphosphonate-paraplegia-spine
description: This skill recommends immediate administration of a potent intravenous bisphosphonate with neurosurgical consultation for patients presenting with paraplegia or progressive spinal stenosis attributable to spinal Paget's disease. Clinical triggers include new-onset paraplegia, worsening lower‑extremity weakness, or spinal stenosis symptoms in a patient with established spinal Paget's disease.
---

# Immediate bisphosphonate for spinal Paget's-associated paraplegia

## STEP 1 — Gather Information
Confirm diagnosis of spinal Paget's disease (prior imaging or biopsy), document onset and progression of paraplegia or spinal stenosis symptoms, perform neurologic exam, obtain MRI spine to assess cord compression and structural integrity, check serum alkaline phosphatase (ALP) and renal function, and arrange neurosurgical consultation.

## STEP 2 — Rule In / Rule Out
Is there known spinal Paget's disease with new or worsening paraplegia/spinal stenosis symptoms?  
- **Yes** → proceed to Step 3.  
- **No** → consider alternative causes (e.g., acute disc herniation, tumor, vascular) and investigate accordingly.

## STEP 3 — Classify or Stratify
Assess MRI for severe structural damage (e.g., vertebral collapse, kyphosis >30°, canal compromise requiring decompression).  
- **Severe structural damage** → proceed to Step 4 with surgical planning.  
- **No severe structural damage** → proceed to Step 4 for medical management.

## STEP 4 — Decide
If no severe structural damage: administer a single 5 mg IV dose of zoledronate (or equivalent potent IV bisphosphonate) and continue neurosurgical consultation for monitoring.  
If severe structural damage: proceed to neurosurgical evaluation for possible decompression while initiating the same IV bisphosphonate peri‑operatively.

## Clinical Guardrails / Mimics / Pitfalls
Do not delay bisphosphonate awaiting surgery unless there is acute instability; avoid relying on oral bisphosphonates for acute neurologic deterioration; monitor for acute phase reaction, hypocalcemia, and renal toxicity after IV zoledronate; do not assume paraplegia is irreversible; ensure vitamin D repletion and calcium supplementation; avoid high‑dose steroids which can worsen bone turnover.

## Concrete Clinical Example
A 68‑year‑old man with known lumbar Paget's disease presents with sudden leg weakness and urinary urgency; MRI shows cord thickening at L1 without vertebral collapse; ALP is elevated; neurosurgery is consulted; he receives zoledronate 5 mg IV; his strength improves over 3‑4 weeks.

**Source:** Paget’s Disease of Bone: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI: 10.1210/jc.2014-2910